Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07225335 · ClinicalTrials.gov registry record · NA
Impact of OptiCreatine on Plasma Creatine and Gastrointestinal Effects in Males and Females
A NA study of Creatine Absorption in Healthy Adults, sponsored by TSI Group.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT07225335: Completed NA study of Creatine Absorption in Healthy Adults, sponsored by TSI Group.
NCT07225335 is a NA study of Creatine Absorption in Healthy Adults that has completed, run by TSI Group. The registered enrollment target is 17 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07225335, a NA study of Creatine Absorption in Healthy Adults, has completed, sponsored by TSI Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to evaluate the novel OptiCreatine formulation, which combines creatine with other bioactive compounds purported to enhance absorption and reduce gastrointestinal (GI) discomfort. Using a randomized, double-blind, crossover design, the study will compare the acute and chronic effects of OptiCreatine versus Creatine monohydrate in healthy, recreationally active adults. Participants will be asked to orally consume both the OptiCreatine and the creatine monohydrate. Primary outcomes include plasma creatine concentrations, gastrointestinal symptomatology, and fluid distribution measured through bioelectrical impedance spectroscopy.
Primary Outcome
the maximum observed plasma concentration (Cmax)
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Creatine Monohydrate
- DIETARY_SUPPLEMENT OptiCreatine
Study Locations (1)
North Carolina
- Applied Physiology Laboratory (Fetzer Hall, Room 025) - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2025-12-19 |
| Phase | NA |
What the finished NCT07225335 record still lists
NCT07225335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Creatine Absorption in Healthy Adults appearing as the primary indexed condition, and to 2 interventions - of which Creatine Monohydrate is the first listed.
NCT07225335 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT07225335 about?
NCT07225335 is a clinical study titled "Impact of OptiCreatine on Plasma Creatine and Gastrointestinal Effects in Males and Females". The study aims to evaluate the novel OptiCreatine formulation, which combines creatine with other bioactive compounds purported to enhance absorption and reduce gastrointestinal (GI) discomfort. Using a randomized, double-blind, crossover design, the study will compare the acute and chronic effects ...
What is the current status of trial NCT07225335?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2025-11-05. Estimated completion is 2025-12-19.
What conditions does trial NCT07225335 study?
This clinical trial studies the following conditions: Creatine Absorption in Healthy Adults.
What interventions are being tested in trial NCT07225335?
The interventions under investigation include: Creatine Monohydrate (DIETARY_SUPPLEMENT), OptiCreatine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07225335?
This trial is sponsored by TSI Group, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07225335 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07225335's enrollment target sits among peer trials
17 1871st of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI